An in silico-guided Approach for Assessing Herb-Drug Interaction Potential: A Case Study with Cudrania tricuspidata leaf Extracts.

Abstract

Cudrania tricuspidata leaf extracts (CLEs) have long been utilized as traditional oriental medicines across Asian countries like Korea, China, and Japan. These extracts are renowned for their therapeutic benefits in addressing inflammation, tumors, obesity, and diabetes, maintaining their status as a pivotal folk remedy. Given the rising trend of combining medicinal herbs with conventional medications, it is imperative to explore the potential herb-drug interactions (HDIs). However, there is a dearth of research on evaluating the HDIs of CLEs. Also, the intricate chemical composition of medicinal herbs presents methodological hurdles in establishing causal relationships between their constituents and HDIs. To overcome these challenges, a combined in silico and in vitro workflow was developed and effectively applied to evaluate the potential HDI of CLEs along with the associated chemical factors. In vitro CYP inhibition assays, CLEs exhibited potent inhibition of CYP1A2 and CYP2C8, with quercetin, kaempferol, and their glycosides identified as the major constituents. In silico analysis based on the prediction tools (ADMETlab2.0 and pkCSM) identified key contributors to CYP inhibition, quercetin and kaempferol. Additionally, molecular docking (MD) analysis validated the binding of ligands (quercetin and kaempferol) to proteins (CYP1A2 and CYP2C8). These findings suggest that CLEs could inhibit CYP1A2 and CYP2C8, aiding in understanding the HDI potential of CLEs for safe clinical application. Furthermore, this approach can be broadly applied to study HDIs of various medicinal herbs, enhancing their therapeutic benefits and reducing adverse reactions by considering chemical profiles relevant to HDI potential in herbal preparations.